Tomorrow, LXRX will be sharing Phase 2b topline results of their LX9211 non-opioid analgesic for DPNP.
LXRX stock has declined 38% since their earnings miss & divestiture of Sotagliflozin in Nov '24.
With significant float lock up, high short-interest, and a potentially positive readout, LXRX is poised for a major move to the upside.
PT1: $0.96
PT2: $1.08
Above $1.38 has potential to squeeze to $1.90.
LXRX stock has declined 38% since their earnings miss & divestiture of Sotagliflozin in Nov '24.
With significant float lock up, high short-interest, and a potentially positive readout, LXRX is poised for a major move to the upside.
PT1: $0.96
PT2: $1.08
Above $1.38 has potential to squeeze to $1.90.
交易結束：達到停損點
okay, i learned that i cant do fundamental analysis. sticking to TA lmao 
just practicing & learning
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
just practicing & learning
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。